Day 1 :
University of Wisconsin Madison School of Medicine and Public Health, USA
Keynote: HIPEC for peritoneal malignancies
Time : 09:40-10:20
Aaron H Chevinsky is the Director of Surgical Oncology at Aurora Health Care in Wisconsin. He has lectured nationally and internationally and has published on many aspects of cancer care. He attended medical school and completed his surgical residency in New York, and completed a surgical oncology fellowship at Ohio State. He has been named to the Top Docs list and has won awards for the development of multidisciplinary cancer care programs. He also appeared on TV and radio to raise awareness and promote cancer screening he remains committed to providing the best cancer care to the patients he treats
The use of HIPEC (Hyperthermic Intraperitoneal Chemotherapy) for the treatment of peritoneal based malignancies has been ongoing in the Unites States and around the globe for well over 20 years. This procedure, which combines debulking of all visible cancer, often with peritonectomy, bowel resection, splenectomy and removal of other intra-abdominal organs with the infusion of chemotherapy heated to 42 degrees centigrade has been very effective in treating several malignancies which tend to involve the peritoneal surfaces, but has not metastasized or invaded deeply into other organs. The most commonly treated malignancies include pseudomyxoma peritonei, appendiceal, gastric, colorectal cancer, ovarian and primary peritoneal cancer, as well as peritoneal mesothelioma and recurrent sarcomas. It is estimated that as many as 50,000 patients a year in the United States may be candidates for a HIPEC procedure. The majority of the cases have used mitomycin C as the chemotherapy of choice, others have used platinum (oxaliplatin, cisplatin and carboplatin) based agents. Most patients with carcinomatosis will die within one year of diagnosis if untreated, and with HIPEC (depending on the initial tumor site) may have as much as a 60-70% five-year survival. In most patients their ascites (which is present in over half the patients) will be controlled and their quality of life will be improved. Studies are ongoing to evaluate the effectiveness of HIPEC in high risk cancers, prone to carcinomatosis, in the adjuvant setting after resection. In gynecologic malignancies, HIPEC has been primarily used in recurrent ovarian cancer, where it has been shown to improve survival and reduce recurrence. Post-operative complications include ileus, respiratory compromise, fluid retention and complications related to chemotherapy absorption (such as pancytopenia). A new HIPEC program was started at Aurora St. Luke’s Medical Center in Milwaukee, Wisconsin in September of 2016. To date we have attempted HIPEC on 10 patients, and have been successful in 9 (in one patient the disease was too extensive for effective debulking). The diagnoses included appendiceal cancer, primary peritoneal cancer, granulosa cell ovarian cancer and colorectal cancer. Our protocol for the evaluation of these complex patients, highlighted the need for multidisciplinary management, the integration of intravenous and intraperitoneal chemotherapy, and the intra-operative and post-operative management will be discussed in detail along with suggestions on how to initiate a HIPEC program at the institution.
Naturopathic Oncologist (FNORI), USA
Keynote: Optimal Diets for Cancer Patients
Time : 10:20-11:00
Dr. Colleen Huber is a Naturopathic Medical Doctor in Tempe, Arizona. Her clinic, Nature Works Best Cancer Clinic, has had the most successful results of any clinic in the world reporting its results over the last 9 years. President of the Naturopathic Cancer Society, whose primary aim is to inform the public of safe and effective natural treatments for: Breast Cancer, Colorectal Cancer, Gastric and Esophageal Cancer, Leukemias and Lymphomas, Liver and Biliary Tract Cancers, Lung Cancer, Ovarian and Uterine Cancers, Pancreatic Cancer, Prostate Cancer, Skin Cancer, General and Other Cancer
Family & Community Medicine, New York Medical College, USA
Keynote: Non-invasive, early detection of various cancers & their metastases using 3 new diagnostic methods developed by the author and safely, effectively treating & preventing cancers using individualized optimal dose of Vitamin D3, which has 7 unique beneficial effects recently discovered, supplemented with optimal dose of EPA & DHA
Time : 11:20- 12:00
Yoshiaki Omura received Oncological Residency training at Cancer Institute of Columbia University & Doctor of Science Degree through research on Pharmaco-Electro-Physiology of Single Cardiac Cells in-vivo and in-vitro from Columbia University. He researched EMF Resonance phenomenon between 2 identical molecules for non-invasive detection of molecules, at Graduate Experimental Physics Dept., Columbia University, for which he received U.S. patent. He is also the creator of Bi-Digital O-Ring Test. He published over 270 original research articles, many chapters, & 9 books. He is currently Adjunct Prof. of Family & Community Medicine, New York Medical College; President & Prof. of Int’l College of Acupuncture & Electro-Therapeutics, NY; Editor in Chief, Acupuncture & Electro-Therapeutics Research, Int’l Journal of Integrative Medicine, (indexed by 17 major int’l Indexing Periodicals); Formerly, he was also Adjunct Prof. or Visiting Prof. in Universities in USA, France, Italy, Ukraine, Japan, Korea, & China.
Any cancer can be non-invasively, quickly, & safely detected using following methods: 1) Visible & invisible changes of accurate organ representation areas at specific part of the face including eyebrows, lips, nose, as well as tongue & hands. 2) One page of “Mouth, Hand, & Foot Writing Form”. 3) New method of detection of various cancers from rapidly changing QRS Complex as well as rising part of T-wave of ECGs. These diagnostic methods were discovered using Bi-Digital O-Ring Test (BDORT) which uses highly sensitive Electromagnetic Field (EMF) resonance phenomenon between 2 identical molecules with identical weight. Using this, most molecules can be detected non-invasively & rapidly. For this, US Patent was given in 1993. Using 1st method, we can suspect some of the cancers from visible, abnormal deep creases of skin or disappearance of parts of eyebrows in the presence of malignancy at corresponding organ representation area as visible changes. However, some of deep crease may not be malignant. Using BDORT, if it is abnormal (-) value of (-)7 or very high negative value of (-)12, immediately malignancy can be suspected. If visible or invisible abnormal area has BDORT (-)7 or higher, using microscope slide of cancer of specific internal organs we can quickly determine by the presence of strong EMF resonance phenomenon without using biopsy which often spreads cancer at cellular level. We can use following 3 non-invasive, quick confirmation methods: 1) Presence of strong EMF resonance phenomenon with microscope slide of specific cancer tissue. 2) Integrin αβ or Oncogene C-fosAb2 is significantly increased. 3) Non-invasive measurement of 8-OH-dG, which is proportional to DNA mutation, which requires for the growth of cancer cells. Early stage cancer is usually 2.5ng but when it is over 10ng or higher, often there is a metastasis. When there is no visible signs of malignancy, we use one-page “Mouth, Hand, & Foot Writing Form” analysis. Its completion by patient after instruction of how to do it, on average it takes about 5-10 minutes for each patient to complete. Once it is completed using cancer-screening kit, which consists of 75 microscope slides of the most common cancers, we can screen any malignancy in less than 1 minute and detection of specific cancer can take anywhere between 5-10 minutes and some patients have more than 3-4 different cancers. Therefore, this 2nd method is most quick, reliable method of making any diagnosis of any cancer or other malignancies without knowing anything about the patient. 3rd method needs strong Physics background on electromagnetic field & the procedure is more time-consuming, experience, & training, since the author discovered this method only 2 years ago, we use it when diagnosis of the patient is questionable and electrocardiogram is already available. In the future, this method may become important cancer-screening test. To prevent cancer, first we screen if there is any indication of early stage of malignancy. When there is early sign of malignancy, Integrin αβ and 8-OH-dG are slightly increased but not detectable by standard laboratory tests. For treatment or prevention we have compared effectiveness of optimal doses of Vitamin D, PPQ, Taurine, & DHEA since we found they are decreased in cancer tissue. However, our recent study revealed 8 unique, beneficial effects of optimal dose of Vitamin D including safe, strong anti-cancer effects. We found individually determined optimal dose of Vitamin D on average 3 times a day because 1 optimal dose of Vitamin D lasts about 8 hours for patient with early stage of cancer. For advanced stage of cancer with metastasis, we use 3~4 times a day with best anti-cancer effects without side effects. When there is no malignancy, optimal dose of Vitamin D for average adult is 400I.U. (10 micrograms). Average dose for pre-cancer (which is before standard laboratory tests in detection) is 600I.U.. For patients with early stage of cancer, optimal dose is about 800I.U.. For those with advanced cancer with metastasis, average optimal dose is between 1000-1600I.U.. All these optimal doses should be determined individually & given every 8 hours. According to the Bi-Digital O-Ring Test, optimal dose for each individual is amount which makes any abnormal (-) value of BDORT to (+)12. Optimal dose can change depending on the patient’s condition. Therefore, it should be reevaluated periodically. As exception, some patients with serious liver & kidney disease, Vitamin D is ineffective but often optimal doses of one of DHEA, Taurine, or PQQ is highly beneficial. However, if you use overdose of Vitamin D such as 2000~5000I.U. or higher, it will promote growth of cancer. One of major problems of current chemotherapy is often individualized optimal dose is rarely used.